Dune Medical Devices is promoting a study that showed its MarginProbe device improved surgical outcomes in patients with ductal carcinoma in situ (DCIS).
An analysis of the MarginProbe postmarket study of patients with DCIS conducted in three centers in Germany was presented during the 2013 Cancer Therapy and Research Center (CTRC)-American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium.
In patients with DCIS, adjunctive use of MarginProbe significantly improved surgical outcomes by increasing the ability of surgeons to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by more than 50%, according to Dune Medical Devices.
